Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
3T Biosciences has named John Connolly interim CEO of the company. Connolly was most recently chief scientific officer at Tessa Therapeutics.
AB2 Bio has appointed Djordje Filipovic as its chief commercial officer. Filipovic most recently served as an executive overseeing the development and commercialization of small molecules and monoclonal antibodies at Novartis.
Aldevron has appointed Matt Johnson vice president of information technologies (IT). Most recently, Johnson was assistant vice president of IT and site operations at Assertio Therapeutics.
Allterum Therapeutics has added Philip Breitfeld to its staff as the company’s new chief medical officer. Prior to this appointment, Breitfeld was the chief strategy and innovation officer at Champions Oncology.
Alnylam Pharmaceuticals has named Tolga Tanguler its new chief commercial officer. Tanguler most recently was the senior vice president and head of U.S. at Alexion.
Erin Whitney has been appointed head of global clinical operations at Amylyx Pharmaceuticals. Formerly, Whitney was director of clinical development operations at bluebird bio. Amylyx has also hired Shauna Horvath, former brand strategy consultant at Amylyx, as head of global marketing. Keith White has been named Amylyx’s head of global market access. White was most recently vice president of global market access and pricing at Corbus Pharmaceuticals.
Christopher Kurtz has been named executive vice president of technical operations at Cidara Therapeutics. Prior to this appointment, Kurtz was the head of commercial API manufacturing at Gilead Sciences.
Scott Burger has been tapped to serve as CorVista Health’s chief commercial officer and vice president. Formerly, Burger was a director in Johnson & Johnson’s cardiovascular group.
Cyclerion Therapeutics has promoted Cheryl Gault from senior vice president and head of strategy and corporate development to chief operating officer.
Erik Rutjens has been hired to serve as Enara Bio’s vice president of cell therapy operations. Rutjens most recently served as head of enabling technologies and process engineering at Novartis.
Dolca Thomas has been named executive vice president of R&D and chief medical officer of clinical-stage biotechnology company Equillium. Thomas was most recently chief medical officer of Principia Biopharma.
Jonathan Zung has been named chief development officer of Evelo Biosciences. Previously, Zung served as the president of sponsor and CRO programs at WCG Clinical.
Michael Mano, former counsel for business development at Biogen, has been appointed senior vice president and general counsel at Karyopharm Therapeutics.
Donald Johns has joined NodThera as the company’s newest chief medical officer. Johns most recently served in the same role at Syntimmune.
Novavax has named Rick Crowley as its new chief operating officer. Crowley was previously the executive vice president of technical operations at TerSera Pharmaceuticals.
Jim Reddoch, co-head of research and investments at Royalty Pharma, has been named chief scientific officer. Royalty Pharma has also promoted Marshall Urist from the role of senior vice president to executive vice president and co-head of research and investments. Sandy Balkin, former head of data and strategy at Truist Securities, has joined Royalty Pharma as its newest senior vice president of strategy and analytics.
Barry Greene, former president of Alnylam, has taken the helm of Sage Therapeutics as its newest CEO.
Clinical-stage biopharmaceutical company Saniona has appointed Kyle Haraldsen to the role of chief technical operations officer. Haraldsen was formerly the vice president of technical operations and project management at AMAG Pharmaceuticals.
Swedish Orphan Biovitrum
Duane Barnes, former president of UCB Pharma, has been named head of North America at Swedish Orphan Biovitrum.
Jeff Ames has been appointed president and CEO of Tekscan. Most recently, Ames was vice president and general manager of Kaman Distribution.